

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Mydecine Innovations Group Inc.
Suite 810 – 789 West Pender Street
Vancouver, BC V6C 1H2

Item 2 Date of Material Change

February 3, 2022

Item 3 News Release

News release issued on February 3, 2022 was disseminated through the facilities of GlobalNewsWire and filed on the System for Electronic Document Analysis and Retrieval (SEDAR) February 3, 2022.

Item 4 Summary of Material Change

Mydecine Innovations Group Inc. ("Mydecine" or the "Company") announced the appointment of a new director to the Board of Directors (the "Board").

Item 5.1 Full Description of Material Change

The Board of Mydecine voted unanimously to appoint Dr. Victoria Hale as the seventh member of the Board. Dr. Hale will join the Board in mid-February, and will be an independent director.

Please refer to the Mydecine news releases dated February 3, 2022 for more detailed information, available on the Company's website at <https://www.mydecine.com/> and on SEDAR at www.sedar.com.

Item 5.2 Disclosure for Restructuring Transactions

Not applicable

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable

Item 7 Omitted Information

Not applicable

Item 8 Executive Officer

David Joshua Bartch,
Chief Executive Officer
604-687-2038
jbartch@mydecineinc.com

Item 9 Date of report:

February 3, 2022